Paper Details

  1. Home
  2. Paper Details

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.

Author: ButtiglieroConsuelo, CastroElena, ChenHsiang-Chun, CzibereAkos, DorffTanya, FizaziKarim, FlemingMark T, HealyCynthia G, HiganoCelestia S, LairdA Douglas, MataMarielena, MehraNiven, SaadFred, ScagliottiGiorgio V, StenzlArnulf, StirlingAdam, de BonoJohann S, van OortInge M

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the effectiveness of the PARP inhibitor talazoparib in treating metastatic castration-resistant prostate cancers with DNA damage response (DDR) alterations. The research focused on the role of PARP inhibitors in targeting cancers with specific genetic vulnerabilities, offering a potential therapeutic strategy for these patients.
Paper Details　
Original Abstract of the Article :
Poly(ADP-ribose) polymerase (PARP) inhibitors have antitumour activity against metastatic castration-resistant prostate cancers with DNA damage response (DDR) alterations in genes involved directly or indirectly in homologous recombination repair (HRR). In this study, we assessed the PARP inhibitor ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1470-2045(21)00376-4

データ提供：米国国立医学図書館（NLM）

Talazoparib: A New Hope for Metastatic Prostate Cancer?

The fight against metastatic castration-resistant prostate cancer (mCRPC) is an ongoing challenge. This study examines the potential of talazoparib, a PARP inhibitor, as a therapeutic option for mCRPC patients with DNA repair alterations. This research explores a promising new avenue for treating this aggressive form of cancer.

Targeting DNA Repair: A Novel Approach

This research takes us deep into the desert of cellular mechanisms, focusing on the intricate dance of DNA repair. By targeting this crucial process, talazoparib offers a novel approach to fighting mCRPC. Imagine a desert traveler, facing a harsh landscape. Talazoparib, like a hidden spring, may offer a vital source of strength in the face of this challenging journey.

Navigating Prostate Cancer: A Journey of Hope and Research

Metastatic castration-resistant prostate cancer is a serious disease, but ongoing research is bringing us closer to effective treatments. It's crucial to consult with your physician to discuss all available options, including clinical trials. Together, we can continue to navigate the desert of prostate cancer research and discover new pathways to hope and healing.

Dr. Camel's Conclusion

This study offers a glimmer of hope in the vast desert of mCRPC research. Talazoparib represents a promising new avenue for treating this challenging disease. By understanding the intricate mechanisms of DNA repair, we can develop more targeted therapies and improve the lives of those battling this aggressive form of cancer. Like a camel traversing a challenging landscape, we must continue to seek knowledge and innovation to find our way to a brighter future.

Date :
  1. Date Completed 2021-09-21
  2. Date Revised 2022-06-02
Further Info :

Pubmed ID

34388386

DOI: Digital Object Identifier

10.1016/S1470-2045(21)00376-4

Related Literature

Article Analysis
・Side Effects of talazoparib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.